Idenix Pharmaceuticals, Inc.

Centre National De La Recherche Scientifique

Merck Sharp + Dohme Corp.

Université Montpellier 2 Sciences Et Techniques

Universitè De Montpellier

Francois-Rene Alexandre

Christophe Parsy

Dominique Surleraux

Cyril B Dousson

David Dukhan

Thierry Convard

Adel M Moussa

Benjamin Alexander Mayes

Claire Pierra

Alistair James Stewart

Florence Marie-Emilie Bonnaterre

Michel Derock

Richard Storer

Frederic Leroy

Houcine Rahali

Gilles J Gosselin

Guillaume Brandt

Jean-Laurent Paparin

Daniel Da Costa

Jing Yang Wang

Jean-Christophe Meillon

Edward Bridges

Arlene Roland

Stephane L Bogen

Izzat Tiedje Raheem

Rachid Rahali

Jean-Francois Griffon

Jean-François Griffon

Claire Pierra Rouviere

Christophe Claude Parsy

Florence Bonnaterre

The present invention is directed carbocyclic nucleoside reverse transcriptase inhibitors compounds of Formula I and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and/or ARC.

Carbocyclic nucleoside reverse transcriptase inhibitors

The present invention relates to Cyclic Phosphate Substituted Nucleoside Compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein in A, B, R, R, R, Q and V are as defined herein. The present invention also relates to compositions comprising a Cyclic Phosphate Substituted Nucleoside Compound, and methods of using the Cyclic Phosphate Substituted Nucleoside Compounds for treating or preventing HCV infection in a patient. 

Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2'-chloro nucleosides according to Formula 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, Z and PD are as described herein.

2'-chloro nucleoside analogs for HCV infection

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, and pharmaceutical compositions and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. 

Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3'-deoxy nucleoside compounds according to Formula 3001a or 3001b: or a pharmaceutically acceptable salts, solvates, stereoisomeric forms, tautomeric forms, or polymorphic forms thereof, wherein PD, Baseand Baseare as provided herein.

3'-deoxy nucleosides for the treatment of HCV

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

3',5&#x2032;-cyclic phosphate prodrugs for HCV infection

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. 

Macrocyclic serine protease inhibitors

Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. 

5,5-fused arylene or heteroarylene hepatitis C virus inhibitors

Provided herein are ruthenium complexes of Formula I, and processes of preparation thereof. Also provided are methods of their use as a metathesis catalyst. 

Phosphinate ruthenium complexes

3',5&#x2032;-cyclic phosphoramidate prodrugs for HCV infection

3-phosphoindole compounds substantially in the form of a single enantiomer useful for the treatment of Flaviviridae virus infections, and particularly for HIV infections are provided. Also provided are pharmaceutical compositions comprising the 3-phosphoindole compounds alone or in combination with one or more other anti-viral agents, processes for their preparation, and methods of manufacturing a medicament incorporating these compounds.

Enantiomerically pure phosphoindoles as HIV inhibitors

Growing community of inventors

Montpellier, France

Francois-Rene Alexandre